If you have NMOSD, you are between the ages of 18 and 60, and you use a smart phone, you may be able to participate in a clinical trial testing a new self-assessment tool app. Compensation provided.

In this study, we want to compare a new drug for multiple sclerosis (MS) with a drug that is already being used. We want to see how the new drug works and if it might be a better option for treating MS.

Are you between 18 and 45 years of age and diagnosed with multiple sclerosis, without MS relapses within the past year? Are you currently prescribed with MS medication? If so, you may be able to participate in a research study examining whether a switch to a high-efficacy medication- Ofatumumab, would work better for you than your current treatment.

The objective of the registry is to create a cohort of patients with NMOSD. This registry will be used for future research, as well as improvements to the diagnosis, treatment, and understanding of NMOSD.

This clinical trial aims to understand how well ALXN-C5IT works over a long time. We want to see if it can prevent relapses and help with disability, walking, and vision. We also want to know how patients feel about their health while using ALXN-C5IT.